GBP5

GBP5 is an interferon-γ-inducible large GTPase that functions as a central integrator of innate immune signaling by promoting NLRP3 inflammasome assembly, facilitating STAT1 nuclear translocation, and exerting antiviral activity through viroporin secretion. GBP5 selectively promotes NLRP3 inflammasome responses to pathogenic bacteria and soluble activators—but not crystalline stimuli—acting as a non-NLR rheostat for caspase-1 activation and IL-1β/IL-18 maturation, with Gbp5-knockout mice showing pronounced defects in inflammasome-dependent inflammation (PMID:22461501). GBP5 physically binds STAT1 and promotes its nuclear translocation to amplify downstream cytokine transcription and innate lymphoid cell expansion, functioning as a co-facilitator rather than a direct transcription factor (PMID:40055493). During RSV infection, GBP5 localizes to the Golgi via its C-terminal isoprenylation motif (C583) and promotes extracellular secretion of the SH viroporin through a KRT9-dependent bridging mechanism, while the viral G protein counteracts GBP5 by inducing DZIP3-mediated K48-ubiquitination and proteasomal degradation (PMID:32796072, PMID:39835811).

1. 2002 Medium

   Cloning of murine GBP5 established it as a GTP-binding protein with a C-terminal isoprenylation motif and alternative splicing producing isoforms with distinct domain architectures, providing the first structural framework for functional studies.

   Evidence cDNA cloning, sequence analysis, and RNase protection assay in mouse

   PMID:12396730

   Open questions at the time

   • No enzymatic or GTPase activity measured
   • Functional consequence of alternative splicing unknown
   • No human ortholog characterized at protein level yet
2. 2004 Medium

   Identification of three human GBP5 splice variants and restriction of protein expression to peripheral blood monocytes in normal tissue established the cell-type specificity relevant to its later-discovered innate immune functions.

   Evidence RT-PCR, isoform-specific western blotting in normal and tumor cell lines

   PMID:15175044

   Open questions at the time

   • Expression in other immune cell types not surveyed comprehensively
   • Functional differences between GBP-5a/5b/5ta isoforms not tested
3. 2012 High

   The central question of whether GBP5 has a defined innate immune effector function was answered: GBP5 selectively promotes NLRP3 inflammasome assembly in response to bacteria and soluble agents but not crystalline activators, establishing it as the first non-NLR/non-ALR rheostat for inflammasome gating.

   Evidence Gbp5 knockout mice, macrophage caspase-1/IL-1β/IL-18 cleavage assays, in vivo infection models, genetic epistasis with Nlrp3

   PMID:22461501

   Open questions at the time

   • Molecular mechanism by which GBP5 distinguishes soluble from crystalline activators unknown
   • Direct physical interaction with NLRP3 or ASC not demonstrated
   • Whether GTPase activity is required for inflammasome function untested
4. 2017 Medium

   GBP5's antiviral repertoire was extended beyond inflammasome activation when it was shown to inhibit influenza A virus replication by interacting with NEMO and stimulating NF-κB signaling, revealing a second effector axis.

   Evidence Co-immunoprecipitation with NEMO, knockdown and overexpression in A549 cells, viral replication assays

   PMID:28376501

   Open questions at the time

   • NEMO interaction not confirmed by reciprocal IP or endogenous pull-down
   • Whether GTPase or isoprenylation motif is needed for NF-κB activation unknown
   • Single cell line tested
5. 2020 High

   The mechanism of GBP5 antiviral activity against RSV was resolved: GBP5 promotes secretion of the RSV SH viroporin via microvesicles, requiring Golgi localization through C583 isoprenylation but not GTPase activity, while RSV counteracts GBP5 through DZIP3-mediated K48-ubiquitination and proteasomal degradation.

   Evidence C-terminal and GTPase-dead mutants, subcellular imaging, RSV replication assays, DZIP3 overexpression/siRNA, proteasome inhibitor rescue

   PMID:32796072

   Open questions at the time

   • Identity of cargo receptor or vesicle machinery linking GBP5 to microvesicle secretion unknown
   • Whether DZIP3-mediated degradation occurs during other viral infections not tested
6. 2021 High

   Multiple studies established that GBP5 transcription is directly regulated by BATF (activating) at the promoter and that GBP5 can activate both intrinsic (calpain/caspase-12/caspase-3) and extrinsic (TNFα/caspase-8/caspase-3) apoptosis in hepatocytes, broadening its cell-death effector functions beyond pyroptosis.

   Evidence ChIP and promoter reporter assays for BATF–GBP5 promoter; Gbp5 KO mice and liver-specific adenoviral overexpression in GalN/LPS injury model with calpain and caspase-3 inhibitor rescue

   PMID:34042221 PMID:34958688

   Open questions at the time

   • Whether apoptosis induction requires GTPase activity or isoprenylation unknown
   • Mechanism linking GBP5 to calpain activation not defined at molecular level
7. 2021 Medium

   GBP5 was placed in oncogenic and immune-evasion signaling: it promotes GBM tumor growth via Src/ERK1/2/MMP3 and sustains PD-L1 expression in TNBC through IFNγ/STAT1 and TNFα/NF-κB axes, indicating context-dependent pro-tumorigenic roles.

   Evidence siRNA/overexpression in GBM and TNBC cell lines, in vivo mouse GBM tumor model, Transwell migration, western blotting for pathway components

   PMID:33608513 PMID:33916322

   Open questions at the time

   • Direct substrates or binding partners mediating Src or ERK activation not identified
   • Whether inflammasome function contributes to tumor phenotypes untested
   • Single-lab studies for each tumor type
8. 2023 Medium

   Two additional transcriptional inputs to GBP5 were defined—IRF1 directly activates the GBP5 promoter to drive NLRP3-mediated chondrocyte pyroptosis, and GBP5 participates in a positive feedback loop with CXCL8 through JAK1-STAT1 signaling—consolidating GBP5 as a convergence node for multiple inflammatory transcription factors.

   Evidence ChIP and dual-luciferase reporter for IRF1; RNA-seq and pathway inhibition for CXCL8 feedback loop in gastric cancer cells

   PMID:37168340 PMID:38229660

   Open questions at the time

   • Whether IRF1, BATF, and HDAC3 act combinatorially on the GBP5 promoter unknown
   • CXCL8 feedback loop demonstrated only in gastric cancer cells
9. 2024 Medium

   HDAC3 was identified as a positive transcriptional regulator of GBP5 in macrophages, linking epigenetic control to inflammasome output, while GBP5 was shown to induce canonical pyroptosis in ovarian cancer cells via JAK2/STAT1 with consequent CXCL9/10/11-driven M1 macrophage recruitment.

   Evidence Conditional Hdac3 KO in CX3CR1+ cells with RNA-seq and reporter assays; GBP5 OE/KD in ovarian cancer cells and patient-derived organoids with immune co-culture

   PMID:38817865 PMID:38903915

   Open questions at the time

   • Whether HDAC3 acts directly on GBP5 promoter chromatin or indirectly through another factor not resolved
   • Relative contribution of pyroptosis vs. chemokine secretion to tumor immune remodeling unclear
10. 2025 High

    The mechanism by which GBP5 amplifies cytokine signaling was resolved: GBP5 physically binds STAT1 and facilitates its nuclear translocation without acting as a transcription factor itself, functioning as a co-facilitator of STAT1 activity that drives innate lymphoid cell expansion in colitis.

    Evidence Reciprocal co-immunoprecipitation, nuclear fractionation, Gbp5 KO mouse colitis model, STAT1 overexpression rescue in GBP5-deficient THP-1 cells

    PMID:40055493

    Open questions at the time

    • Domain on GBP5 mediating STAT1 binding not mapped
    • Whether GBP5 also facilitates nuclear translocation of other STATs unknown
11. 2025 Medium

    KRT9 was identified as the obligate partner bridging GBP5 to RSV-SH protein for antiviral viroporin secretion, with a mapped GBP5-binding domain on KRT9, explaining the cargo-specificity of the GBP5 secretory antiviral pathway. ERRγ was identified as a transcriptional repressor of GBP5 that suppresses inflammasome-mediated cardiomyocyte pyroptosis after myocardial infarction.

    Evidence Affinity mass spectrometry and Co-IP for KRT9–GBP5 interaction, KRT9 siRNA abolishing antiviral effect; ERRγ promoter binding assay and in vivo epistasis in cardiomyocytes

    PMID:39835811 PMID:40636987

    Open questions at the time

    • Whether KRT9–GBP5 interaction occurs in non-RSV antiviral contexts unknown
    • ERRγ-GBP5 axis demonstrated only in cardiomyocytes; generalizability untested

• Key unresolved questions include: (1) the structural basis and direct binding interface for GBP5-NLRP3/ASC interaction, (2) whether GTPase activity is dispensable for all GBP5 functions or only for RSV-related secretion, (3) the integration of multiple transcriptional inputs (BATF, IRF1, HDAC3, ERRγ) at the GBP5 promoter, and (4) the molecular mechanism by which GBP5 distinguishes soluble from crystalline NLRP3 activators.
• No crystal structure or cryo-EM of GBP5 alone or in complex
• No reconstituted in vitro inflammasome assembly with purified GBP5
• Isoform-specific functions of GBP-5a/5b/5ta remain untested